Increased level of p63RhoGEF and RhoA/Rho kinase activity in hypertensive patients

Journal of Hypertension

Volumn 32, Issue 2, 2014, Pages 331-338

  Calò, Lorenzo A ^a   Davis, Paul A ^b   Pagnin, Elisa ^a   Dal Maso, Lucia ^a   Maiolino, Giuseppe ^a   M Seccia, Teresa ^a   Pessina, Achille C ^a   Rossi, Gian Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

angiotensin II signaling; cardiovascular remodeling; hypertension; p63RhoGEF; Rho kinase

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; MESSENGER RNA; MYOSIN; MYOSIN PHOSPHATASE TARGET PROTEIN 1; PHOSPHATASE; PROTEIN P63; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR; RHO KINASE; UNCLASSIFIED DRUG;

ADULT; ANGIOTENSIN BLOOD LEVEL; ARTICLE; BARTTER SYNDROME; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE;

ADULT; ANGIOTENSIN II; BARTTER SYNDROME; BLOOD PRESSURE; CASE-CONTROL STUDIES; FEMALE; GITELMAN SYNDROME; HUMANS; HYPERTENSION; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYOSIN-LIGHT-CHAIN PHOSPHATASE; PHOSPHORYLATION; RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; SOLUTE CARRIER FAMILY 12, MEMBER 3;

EID: 84892958367     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000075     Document Type: Article

References (32)

1. Mehta PK, Griendling KK. Angiotensin II cell signaling. Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 92:C82-C97.
2. Tabet F, Schiffrin EL, Callera GE, He Y, Yao G, Ostman A, et al. Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ Res 2008; 103:149-158.
3. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98:322-334.
4. Calò LA, Pessina AC. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens 2007; 25:259-264.
5. Wirth A. Rho kinase and hypertension. Biochim Biophys Acta 2010; 1802:1276-1284.
6. Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Nat Rev Cardiol 2010; 7:637-647.
7. Wuertz MC, Lorincz A, Vettel C, Thomas MA, Wieland T, Lutz S. p63RhoGEF- A key mediator of angiotensin II dependent signaling and processes in vascular smooth muscle cells. FASEB J 2010; 24:4865-4876.
8. Shankaranarayanan A, Boguth CA, Lutz S, Vettel C, Uhlemann F, Aittaleb M, et al. Galpha q allosterically activates and relieves auto-inhibition of p63RhoGEF. Cell Signal 2010; 22:1114-1123.
9. Momotani K, Artamonov MV, Utepbergenov D, Derewenda U, Derewenda ZS, Somlyo AV. p63RhoGEF couples Gaq/11-mediated signaling to Ca2+ sensitization of vascular smooth muscle contractility. Circ Res 2011; 109:993-1002.
10. Guilluy C, Brégeon J, Toumaniantz G, Rolli-Derkinderen M, Retailleau K, Loufrani L, et al. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med 2010; 16:183-190.
11. Naesens M, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D. Bartter's and Gitelman's syndromes: from gene to clinic. Nephron Physiol 2004; 96:65-78.
12. Calò LA. Vascular tone control in humans: the utility of studies in Bartter's/Gitelman's syndromes. Kidney Int 2006; 69:963-966.
13. Calò LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC, et al. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 2004; 89:4153-4157.
14. Calò LA, Pagnin E, Ceolotto G, Davis PA, Schiavo S, Papparella I, et al. Silencing regulator of G protein signaling-2 (RGS-2) increases angio-tensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes. J Hypertens 2008; 26:938-945.
15. Shankaranarayanan A, Thal DM, Tesmer VM, Roman DL, Neubig RR, Kozasa T, et al. Assembly of high order G alpha q-effector complexes with RGS proteins. J Biol Chem 2008; 283:34923-34934.
16. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.
17. Hilgers KF. Monocytes/macrophages in hypertension. J Hypertens 2002; 20:593-596.
18. Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension 2002; 39:777-780.
19. Noma K, Kihara Y, Higashi Y. Striking crosstalk of ROCK signaling with endothelial function. J Cardiol 2012; 60:1-6.
20. Hata T, Soga J, Hidaka T, Idei N, Fujii Y, Fujimura N, et al. Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. J Hypertens 2011; 29:373-379.
21. Pagnin E, Semplicini A, Sartori M, Pessina AC, Calò LA. Reduced mRNA and protein content of Rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes: relevance for the pathophysiology of hypertension. Am J Hypertens 2005; 18:1200-1205.
22. Semplicini A, Lenzini L, Sartori M, Papparella I, Calò LA, Pagnin E, et al. Reduced expression of regulator of G protein signaling-2 in hypertensive patients increases calcium mobilization and ERK1/2 phos-phorylation induced by angiotensin II. J Hypertens 2006; 24:1115-1124.
23. Erne P, Bürgisser E, Bolli P, Ji BH, Bühler FR. Free calcium concentration in platelets closely relates to blood pressure in normal and essentially hypertensive subjects. Hypertension 1984; 6:I166-I169.
24. Baritono E, Ceolotto G, Papparella I, Sartori M, Ciccariello L, Iori E, et al. Abnormal regulation of G protein alpha(i2) subunit in skin fibroblasts from insulin-resistant hypertensive individuals. J Hypertens 2004; 22:783-792.
25. Calò LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D'Angelo A, et al. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. J Hypertens 2010; 28:111-118.
26. Calò LA, Puato M, Schiavo S, Zanardo M, Tirrito C, Pagnin E, et al. Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. Nephrol Dial Transplant 2008; 23:2804-2809.
27. Calò LA, Montisci R, Scognamiglio R, Davis PA, Pagnin E, Schiavo S, et al. High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes). Are angiotensin II type 2 receptors involved? J Endocrinol Invest 2009; 32:832-836.
28. Calò L, Sartore G, Bassi A, Basso C, Bertocco S, Marin R, et al. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome). J Hypertens 1998; 16:1001-1008.
29. Calò LA, Pagnin E, Davis PA, Sartori M, Semplicini A. Oxidative stress related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant 2003; 18:1518-1525.
30. Calò LA, Facco M, Davis PA, Pagnin E, Dal Maso L, Puato M, et al. Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling. Hypertens Res 2011; 34:1017-1022.
31. Calò LA, Davis PA, Pagnin E, Dal Maso L, Caielli P, Rossi GP. Calcitonin gene-related peptide, heme oxygenase-1, endothelial progenitor cells and nitric oxide-dependent vasodilation relationships in a human model of angiotensin II type-1 receptor antagonism. J Hypertens 2012; 30:1406-1413.
32. Savoia C, Tabet F, Yao G, Schiffrin EL, Touyz RM. Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens 2005; 23:1037-1045.